Literature DB >> 10846070

Additive effect of neutralizing antibody and antiviral drug treatment in preventing virus escape and persistence.

P Seiler1, B M Senn, P Klenerman, U Kalinke, H Hengartner, R M Zinkernagel.   

Abstract

Poorly cytopathic or noncytopathic viruses can escape immune surveillance and establish a chronic infection. Here we exploited the strategy of combining antiviral drug treatment with the induction of a neutralizing antibody response to avoid the appearance of neutralization-resistant virus variants. Despite the fact that H25 immunoglobulin transgenic mice infected with lymphocytic choriomeningitis virus mounted an early neutralizing antibody response, the virus escaped from neutralization and persisted. After ribavirin treatment of H25 transgenic mice, the appearance of neutralization-resistant virus was prevented and virus was cleared. Thus, the combination of virus-neutralizing antibodies and chemotherapy efficiently controlled the infection, whereas each defense line alone did not. Similar additive effects may be unexpectedly efficient and beneficial in humans after infections with persistent viruses such as hepatitis C virus and hepatitis B virus and possibly human immunodeficiency virus.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10846070      PMCID: PMC112085          DOI: 10.1128/jvi.74.13.5896-5901.2000

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  62 in total

1.  Requirement for theta-bearing cells in lymphocytic choriomeningitis virus-induced central nervous system disease.

Authors:  G A Cole; N Nathanson; R A Prendergast
Journal:  Nature       Date:  1972-08-11       Impact factor: 49.962

2.  Lymphocytic choriomeningitis virus. VI. Isolation of a glycoprotein mediating neutralization.

Authors:  M Bruns; J Cihak; G Müller; F Lehmann-Grube
Journal:  Virology       Date:  1983-10-15       Impact factor: 3.616

3.  HTLV-III-neutralizing antibodies in patients with AIDS and AIDS-related complex.

Authors:  M Robert-Guroff; M Brown; R C Gallo
Journal:  Nature       Date:  1985 Jul 4-10       Impact factor: 49.962

4.  Neutralization of human T-lymphotropic virus type III by sera of AIDS and AIDS-risk patients.

Authors:  R A Weiss; P R Clapham; R Cheingsong-Popov; A G Dalgleish; C A Carne; I V Weller; R S Tedder
Journal:  Nature       Date:  1985 Jul 4-10       Impact factor: 49.962

5.  The role of somatic mutation in the generation of the protective humoral immune response against vesicular stomatitis virus.

Authors:  U Kalinke; E M Bucher; B Ernst; A Oxenius; H P Roost; S Geley; R Kofler; R M Zinkernagel; H Hengartner
Journal:  Immunity       Date:  1996-12       Impact factor: 31.745

6.  Antibody prevents the establishment of persistent arenavirus infection in synergy with endogenous T cells.

Authors:  J R Baldridge; T S McGraw; A Paoletti; M J Buchmeier
Journal:  J Virol       Date:  1997-01       Impact factor: 5.103

7.  Complete sequence of the S RNA of lymphocytic choriomeningitis virus (WE strain) compared to that of Pichinde arenavirus.

Authors:  V Romanowski; Y Matsuura; D H Bishop
Journal:  Virus Res       Date:  1985-09       Impact factor: 3.303

8.  Enhanced treatment of Lassa fever by immune plasma combined with ribavirin in cynomolgus monkeys.

Authors:  P B Jahrling; C J Peters; E L Stephen
Journal:  J Infect Dis       Date:  1984-03       Impact factor: 5.226

9.  Lassa virus infection of rhesus monkeys: pathogenesis and treatment with ribavirin.

Authors:  P B Jahrling; R A Hesse; G A Eddy; K M Johnson; R T Callis; E L Stephen
Journal:  J Infect Dis       Date:  1980-05       Impact factor: 5.226

10.  Dengue viruses and mononuclear phagocytes. I. Infection enhancement by non-neutralizing antibody.

Authors:  S B Halstead; E J O'Rourke
Journal:  J Exp Med       Date:  1977-07-01       Impact factor: 14.307

View more
  10 in total

Review 1.  Immunological memory ≠ protective immunity.

Authors:  Rolf M Zinkernagel
Journal:  Cell Mol Life Sci       Date:  2012-04-06       Impact factor: 9.261

Review 2.  Viral quasispecies evolution.

Authors:  Esteban Domingo; Julie Sheldon; Celia Perales
Journal:  Microbiol Mol Biol Rev       Date:  2012-06       Impact factor: 11.056

3.  Role of interferon regulatory factor 7 in T cell responses during acute lymphocytic choriomeningitis virus infection.

Authors:  Shenghua Zhou; Anna M Cerny; Katherine A Fitzgerald; Evelyn A Kurt-Jones; Robert W Finberg
Journal:  J Virol       Date:  2012-08-08       Impact factor: 5.103

4.  Efficient virus extinction by combinations of a mutagen and antiviral inhibitors.

Authors:  N Pariente; S Sierra; P R Lowenstein; E Domingo
Journal:  J Virol       Date:  2001-10       Impact factor: 5.103

Review 5.  Viral escape mechanisms--escapology taught by viruses.

Authors:  M Lucas; U Karrer; A Lucas; P Klenerman
Journal:  Int J Exp Pathol       Date:  2001-10       Impact factor: 1.925

6.  Increased memory conversion of naïve CD8 T cells activated during late phases of acute virus infection due to decreased cumulative antigen exposure.

Authors:  Georgia Fousteri; Amy Dave; Amy Juedes; Therese Juntti; Bret Morin; Lisa Togher; Donna L Farber; Matthias von Herrath
Journal:  PLoS One       Date:  2011-01-06       Impact factor: 3.240

7.  Nonneutralizing antibodies binding to the surface glycoprotein of lymphocytic choriomeningitis virus reduce early virus spread.

Authors:  Lars Hangartner; Raphaël M Zellweger; Mattia Giobbi; Jacqueline Weber; Bruno Eschli; Kathy D McCoy; Nicola Harris; Mike Recher; Rolf M Zinkernagel; Hans Hengartner
Journal:  J Exp Med       Date:  2006-07-31       Impact factor: 14.307

8.  Antigen experience shapes phenotype and function of memory Th1 cells.

Authors:  Aaruni Khanolkar; Matthew A Williams; John T Harty
Journal:  PLoS One       Date:  2013-06-07       Impact factor: 3.240

9.  Determinants of human immunodeficiency virus type 1 escape from the primary CD8+ cytotoxic T lymphocyte response.

Authors:  Nicola A Jones; Xiping Wei; Darren R Flower; Mailee Wong; Franziska Michor; Michael S Saag; Beatrice H Hahn; Martin A Nowak; George M Shaw; Persephone Borrow
Journal:  J Exp Med       Date:  2004-11-15       Impact factor: 14.307

10.  Treatment of COVID-19 with remdesivir in the absence of humoral immunity: a case report.

Authors:  Matthew S Buckland; James B Galloway; Caoimhe Nic Fhogartaigh; Luke Meredith; Nicholas M Provine; Stuart Bloor; Ane Ogbe; Wioleta M Zelek; Anna Smielewska; Anna Yakovleva; Tiffeney Mann; Laura Bergamaschi; Lorinda Turner; Frederica Mescia; Erik J M Toonen; Carl-Philipp Hackstein; Hossain Delowar Akther; Vinicius Adriano Vieira; Lourdes Ceron-Gutierrez; Jimstan Periselneris; Sorena Kiani-Alikhan; Sofia Grigoriadou; Devan Vaghela; Sara E Lear; M Estée Török; William L Hamilton; Joanne Stockton; Josh Quick; Peter Nelson; Michael Hunter; Tanya I Coulter; Lisa Devlin; John R Bradley; Kenneth G C Smith; Willem H Ouwehand; Lise Estcourt; Heli Harvala; David J Roberts; Ian B Wilkinson; Nick Screaton; Nicholas Loman; Rainer Doffinger; Paul A Lyons; B Paul Morgan; Ian G Goodfellow; Paul Klenerman; Paul J Lehner; Nicholas J Matheson; James E D Thaventhiran
Journal:  Nat Commun       Date:  2020-12-14       Impact factor: 17.694

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.